The National Cancer Institute (NCI), Surgery Branch, plans to procure on a sole source basis, services for the Development of p53 TCR lentiviral vectors with Lentigen Corporation, 1450 South Rolling Road, Suite 4.049, Baltimore, MD 21075. This acquisition will be processed under FAR Part 13 for Simplified Acquisitions. The North American Industry Classification System Code is 325413 and the business size standard is 500 employees. p53 TCR lentiviral vectors has been extensively studied as a potential target for cancer therapy because it is mutated in approximately half of all human cancers, leading to a prolonged protein half-life and subsequent over-expression. Additionally, mutant p53 is thought to have a dominant transforming function in vivo, resulting in selection pressure to maintain its expression throughout tumor growth. NCI shall develop lentiviral vectors that can be used to engineer primary human T lymphocytes to express a murine anti-human p53 T-cell receptor, which can both recognize and be able to kill p53-expressing human tumors. The unique ability of lentiviral vectors to transduce human nondividing cells stably and efficiently without expressing immunogenic viral components is a tremendous asset for gene therapy. Like their gammaretrovirus-based predecessors, lentiviral vectors integrate their cargo into the chromosomes of target cells without transferring virus-derived coding sequences. Lentiviral vectors can mediate this process in nondividing cells, which is a great asset for many experimental and clinical situations. Lentigen has the unique technology and expertise to produce lentiviral vectors containing NCI anti-p53 TCRs. The unique ability of the lentiviral vectors is to transduce human non-dividing cells stably and efficiently without expressing immunogenic viral components. Lentiviral vectors integrate their cargo into the chromosomes of target cells without transferring virus-derived coding sequences. Lentigen Corporation is the only known source that can develop lentiviral vectors containing NCI anti-p53 with the unique ability to transduce human non-dividing cells stably and efficiently without expressing immunogenic viral components. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the researcher to determine if the party can perform this requirement. One (1) original and one (1) copy of the capability statement must be received in the contracting office by 1:00 pm EDT on April 27, 2006, 2006. All questions must be in writing and can be faxed to 301-402-4513 or sent via email to [email protected]. It is the vendor’s responsibility to call 301-402-4509 or email Malinda Holdcraft, Contract Specialist to insure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractor must be registered in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA). Please reference NCI-60055-NG on all correspondence.

Bid Protests Not Available